#United States #Boston #oncology #Perceptive Discovery #Radiochemistry

Perceptive Discovery Enhances Preclinical Capabilities with Strategic Investments

Perceptive Discovery, a prominent division specializing in preclinical and translational services, has recently announced its commitment to significantly boost its operational framework with a series of strategic investments totaling $15 million. This move underscores the company's dedication to advancing its capabilities in radiochemistry, cell assay development, and in vitro biology, ultimately aiming to enhance the quality of preclinical workflows for oncology and radiopharmaceutical programs.

Major Expansion in Radiochemistry

One of the most critical aspects of this initiative is the substantial expansion of Perceptive Discovery's Astatine-211 (At-211) infrastructure. This enhancement will take place across two key locations in the U.S. and the U.K., facilitating the installation of new systems and the development of specialized research environments. The hiring of experienced scientific personnel is a priority as well, as it aligns with the company’s objective of providing outstanding services in At-211 labeling, method development, and a range of preclinical applications. Notably, this investment will allow Perceptive Discovery to address the fast-growing demand for alpha-emitting isotopes, positioning the company at the forefront of advancements in radioligand therapies (RLT).

Enhancing Cell Assay Capabilities

In addition to bolstering radiochemistry, Perceptive Discovery is streamlining its workflow by integrating in-house hot assay development capabilities. This venture builds upon existing strengths in radiochemistry and in-vivo biology, fostering a more cohesive scientific process for assay development, characterization, and downstream evaluation. By establishing these internal capabilities, the company enhances operational continuity, improves study execution efficiency, and offers sponsors a broader range of oncology services.

Upgrading In Vitro Biology Facilities

Moreover, the investment will facilitate a thorough upgrade of Perceptive Discovery's in vitro biology facility, a central element of its research infrastructure. This upgraded facility will not only feature increased laboratory space and enhanced equipment but will also see the addition of expert personnel dedicated to supporting consistent tumor growth and a broader array of assay platforms. Such improvements are crucial for ensuring the organization can adapt to and fulfil the evolving needs of its sponsors.

Leadership Insight

Ben Murphy, the Chief Executive Officer, expressed that these substantial investments highlight Perceptive Discovery’s commitment to proactively addressing the evolving demands of its partners. “Our continuous expansion and enhancement of integrated capabilities will enable us to deliver high-quality, decision-ready data to our customers—from discovery through to early clinical translation,” Murphy stated. He emphasized the goal of providing exceptional science backed by robust infrastructure that fosters therapeutic innovation effectively.

Vision for the Future

Kate Briant, Senior Partner at CapVest Partners LLP, reiterated their confidence in the leadership and scientific vision of Perceptive Discovery. She commented on the critical nature of these investments, which aim to cement the company’s role as a key partner for innovators in oncology and radiopharmaceutical sectors—a market projected to be increasingly active in forthcoming years.

About Perceptive Discovery

Perceptive Discovery is dedicated to providing leading preclinical and translational solutions designed to bridge the gap between scientific innovation and early-phase clinical success. With extensive expertise in radiochemistry, in-vivo imaging, dosimetry, assay development, and radioligand therapy, the company is poised to support biotechnology and pharmaceutical partners with invaluable integrated workflows and high-quality data.

For further details, visit www.perceptive.com.